Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis
Sherko Kümmel(Kliniken Essen-Mitte), Miguel Martín(Hospital General Universitario Gregorio Marañón), Carlo Tondini(Ospedale Papa Giovanni XXIII), Servando Cardona‐Huerta(Tecnológico de Monterrey), A. Crepelle-Fléchais(Roche (Switzerland)), Zbigniew Nowecki(The Maria Sklodowska-Curie National Research Institute of Oncology), Erika Hitre(National Institute of Oncology), Bogusława Karaszewska(State University of Applied Sciences in Konin), Jianjun He(Hebei Medical University), Anh Nguyen Duc(Roche (Switzerland)), José García(Vall d'Hebron Hospital Universitari), Flavia Morales-Vásquez(Secretaria de Salud), A. Juárez, Dominik Heinzmann(Roche (Switzerland)), J. Abraham(Velindre Cancer Centre), Bartosz Itrych(Centralny Szpital Kliniczny)
Cited by 3
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k